EDITION:

Search
Search
Close this search box.

Swiss expo to explore European cannabis legalisation

Home » Swiss expo to explore European cannabis legalisation

This year’s CB Expo for CBD and medical cannabis is giving companies products, brands and services the opportunity to network and discover Switzerland’s potential for producing and importing cannabis products.

Since the beginning of August, medical cannabis can be prescribed by doctors in Switzerland without a licence from the health ministry (FOPH). The export of cannabis is now permitted and the first products from the pilot trials in Basel will be  going over the counter this autumn. 

The Swiss cannabis industry is developing, and the second edition of the Cannabis Business Expo (CB Expo) on 10 and 11 September in Zurich, will explore trends in the industry and the discussion about legalisation models in Europe.

Discover more cannabis events on the Cannabis Wealth event page

Main topics at the event will include the pilot projects in Switzerland, as well as the market development for recreational use of cannabis in the country.

Swiss company, Vigia, the company behind the compliance software Cannavigia, is taking part in the CB Expo and will be a Gold Sponsor at this year’s edition.

CEO of Vigia, Luc Richner, commented: “The CB Expo is the perfect opportunity to further network with the European, and especially the Swiss industry, to gain potential customers and to exchange information about the upcoming legalisation in Europe.

“Especially in our still young but rapidly growing industry, it is essential to work together. 

“CB Expo is an excellent trade fair  and gives our industry a good platform to advance the discourse. As a Gold Sponsor, we want to support exactly that and draw attention to the emerging cannabis industry in  Switzerland”.

Vigia is also actively participating in this discourse and is involved in the pilot projects. 

With its track and trace software solution  Cannavigia, the company is an official partner of the FOPH (Federal Office for Public Health) for the pilot trials, allowing cannabis in the trial to be digitised and tracked from cultivation through to processing and distribution. This generates transparency, complete traceability of the cannabis sold and trust. 

[activecampaign form=31]

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?